3-(3-benzyloxy-phenyl)-propionic acid methyl ester | 476458-89-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-(3-benzyloxy-phenyl)-propionic acid methyl ester
• 英文别名: 3-(3-Benzyloxy-phenyl)-propionsaeure-methylester；Methyl 3-[3-(benzyloxy)phenyl]propanoate；methyl 3-(3-phenylmethoxyphenyl)propanoate
• CAS: 476458-89-6
• 化学式: C₁₇H₁₈O₃
• 分子量: 270.328
• InChiKey: TXAJWLXWNZRELC-UHFFFAOYSA-N

物化性质

• 沸点：
  390.1±22.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-benzyloxy-phenyl)-propionic acid methyl ester 在 palladium on activated charcoal lithium hydroxide 、 2,4,6-三异丙基苯磺酰叠氮化物 、 甲基溴化镁 、 氢气 、 三甲基乙酰氯 、 双(三甲基硅烷基)氨基钾 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 methyl (S)-2-amino-3-(3-hydroxyphenyl)propanoate
  参考文献：
  名称：

  Development of tripeptidyl farnesyltransferase inhibitors

  摘要：

  The first example of tripeptide inhibitors of farnesyltransferase with sub-micromolar inhibition activity was developed based on the fact that CVFM is not a substrate for farnesyltransferase. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00227-5
• 作为产物：
  描述：

  3-苄氧基苯甲醛 在 palladium on activated charcoal 氢气 、 sodium methylate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-(3-benzyloxy-phenyl)-propionic acid methyl ester
  参考文献：
  名称：

  Synthesis and Biological Activity of New 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Synthase Inhibitors: 2-Oxetanones with a Side Chain Mimicking the Folded Structure of 1233A.

  摘要：

  为模拟1233A（1）的折叠侧链构象，该化合物是一种3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）合酶抑制剂，合成了侧链含有芳环的1233A类似物。其中2-恶坦酮部分保持不变。在1233A及其合成类似物中，反式-3-羟甲基-4-[2-(7-甲氧羰基-1-萘基)乙基]-2-恶坦酮（23）显示了最高的HMG-CoA合酶体外抑制活性。讨论了侧链上的构效关系。

  DOI：

  10.1248/cpb.42.512

文献信息

• [EN] CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] AGONISTES CYCLOHEXYLE DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018081047A1

  公开（公告）日：2018-05-03

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: (Formula (I)) wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: (Formula (II)) wherein R1B, WB, LB, and GB are defined herein.

  披露了用于治疗受GPR40受体调节影响的疾病的化合物、组合物和方法。这类化合物由公式(I)表示，如下所示：(公式(I))，其中R1、R2、R3、A、W、L、Ra和G在本文中定义；以及由公式(II)表示，如下所示：(公式(II))，其中R1B、WB、LB和GB在本文中定义。
• Synthesis and Biological Activity of New 3-Hydroxy-3-methylglutaryl-CoA Synthase Inhibitors: 2-Oxetanones with a meta-Substituent on the Benzene Ring in the Side Chain.
  作者：Hirokazu HASHIZUME、Hajime ITO、Naoaki KANAYA、Hajime NAGASHIMA、Hiroyuki USUI、Reiko OSHIMA、Munefumi KANAO、Hiroshi TOMODA、Toshiaki SUNAZUKA、Hidetoshi KUMAGAI、Satoshi OMURA

  DOI：10.1248/cpb.42.1272

  日期：——

  Isosteric side chain analogs of 3a were synthesized and tested for inhibitory activivies towards 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) synthase and upon cholesterol production in Hep G2 cells and in mouse liver. It became clear that the lipophilic substituent on the aromatic ring and the terminal hydrophilic group in the side chain were important in the enhancement of activity. 4-[2-(3-n-Hexyloxyphanyl)ethyl]-3-hydroxymethyl-2-oxetanone (5a) showed equivalent inhibitory activity in vivo to that of 1233A.

  同位素侧链类似物3a被合成并测试了对3-羟基-3-甲基戊二酰辅酶A（HMG-CoA）合酶以及在Hep G2细胞和小鼠肝脏中胆固醇生成的抑制活性。结果表明，芳环上的亲脂性取代基和侧链末端的亲水性基团对活性的增强非常重要。4-[2-(3-正己氧基苯基)乙基]-3-羟甲基-2-氧杂环丁酮（5a）在体内的抑制活性与1233A相当。
• SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS AND METHOD
  申请人：Cheng T. W. Peter

  公开号：US20070287713A1

  公开（公告）日：2007-12-13

  wherein Z 1 is (CH 2 ) q or C═O; Z 2 is (CH 2 ) p or C═O; D is —CH═ or C═O or (CH 2 ) m where m is 0, 1, 2 or 3; n=0, 1 or 2; p=1 or 2; q=0, 1 or 2; Q is C or N; A is (CH 2 ) x where x is 1 to 5, or A is (CH 2 ) x 1 , where x 1 is 1 to 5 with an alkenyl bond or an alkynyl bond embedded anywhere in the chain, or A is —(CH 2 ) x 2 —O—(CH 2 ) x 3 — where x 2 is 0 to 5 and x 3 is 0 to 5, provided that at least one of x 2 and x 3 is other than 0; B is a bond or is (CH 2 ) x 4 where x 4 is 1 to 5; X is CH or N; X 2 is C, N, O or S; X 3 is C, N, O or S; X 4 is C, N, O or S; X 5 is C, N, O or S; X 6 is C, N, O or S; provided that at least one of X 2 , X 3 , X 4 X 5 and X 6 is N; and at least one of X 2 , X 3 , X 4 X 5 and X 6 is C. R 1 is H or alkyl; R 2 is H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; R 2a , R 2b and R 2c may be the same or different and are selected from H, alkyl, alkoxy, halogen, amino, substituted amino or cyano; and R 3 , E, Z and Y are as defined herein.

  其中Z1为(CH2)q或C═O；Z2为( )p或C═O；D为—CH═或C═O或( )m，其中m为0、1、2或3；n=0、1或2；p=1或2；q=0、1或2；Q为C或N；A为( )x，其中x为1到5，或A为( )x1，其中x1为1到5，具有烯丙基键或炔基键嵌入链中的任何位置，或A为—( )x2—O—( )x3—，其中x2为0到5，x3为0到5，前提是x2和x3中至少有一个不为0；B为键或( )x4，其中x4为1到5；X为CH或N；X2、X3、X4、X5和X6为C、N、O或S；前提是X2、X3、X4、X5和X6中至少有一个为N；并且X2、X3、X4、X5和X6中至少有一个为C。R1为H或烷基；R2为H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；R2a、R2b和R2c可以相同也可以不同，选择自H、烷基、烷氧基、卤素、氨基、取代氨基或氰基；而R3、E、Z和Y的定义如前所述。
• Antihypertensive dihydropyridine derivatives
  申请人：LABORATOIRES SYNTEX S.A.

  公开号：EP0249245A2

  公开（公告）日：1987-12-16

  Compounds of formula 1 as their racemic mixtures or optical isomers are calcium entry antagonists useful for treating hypertension, congestive heart failure, angina, and vasospastic disorders: wherein n is an integer from 1 to 4; R1 and R2 are lower alkyl; R3 is lower alkyl or alkoxyalkyl; A is alkylene of two to eight carbon atoms; X1 and X2 are each independently -N02, -CF3, CH30-, -CN, -H, lower alkyl or halo; Y is -O-, -S-, -S(O)-, or -S(O)2-; and R is H or R' wherein R' is lower alkyl, cycloalkyl, alkoxyalkyl, cycloalkyloxy-alkyl, alkoxycycloalkyl, acyl, or saturated or unsaturated 5-or 6-membered heterocyclyl optionally substituted with lower alkyl or alkoxy, wherein the heteroatom is one oxygen atom.

  式 1 的化合物作为其外消旋混合物或光学异构体是钙离子进入拮抗剂，可用于治疗高血压、充血性心力衰竭、心绞痛和血管痉挛性疾病： 其中 n 是 1 到 4 的整数；R1 和 R2 是低级烷基；R3 是低级烷基或烷氧基烷基；A 是 2 到 8 个碳原子的亚烷基；X1 和 X2 各自独立地是-N02、-CF3、CH30-、-CN、-H、低级烷基或卤代；Y 是-O-、-S-、-S(O)- 或-S(O)2-；R是H或R'，其中R'是低级烷基、环烷基、烷氧基烷基、环烷氧基烷基、烷氧基环烷基、酰基或饱和或不饱和的5或6元杂环烷基，可任选被低级烷基或烷氧基取代，其中杂原子是一个氧原子。
• Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists
  作者：Wei Wang、Pratik Devasthale、Dennis Farrelly、Liqun Gu、Thomas Harrity、Michael Cap、Cuixia Chu、Lori Kunselman、Nathan Morgan、Randy Ponticiello、Rachel Zebo、Litao Zhang、Kenneth Locke、Jonathan Lippy、Kevin O’Malley、Vinayak Hosagrahara、Lisa Zhang、Pathanjali Kadiyala、Chiehying Chang、Jodi Muckelbauer、Arthur M. Doweyko、Robert Zahler、Denis Ryono、Narayanan Hariharan、Peter T.W. Cheng

  DOI：10.1016/j.bmcl.2008.01.126

  日期：2008.3

  A novel class of azetidinone acid-derived dual PPAR alpha/gamma agonists has been synthesized for the treatment of diabetes and dyslipidemia. The preferred stereochemistry in this series for binding and functional agonist activity against both PPAR alpha and PPAR gamma receptors was shown to be 3S,4S. Synthesis, in vitro and in vivo activities of compounds in this series are described. A high-yielding method for N-arylation of azetidinone esters is also described. (C) 2008 Elsevier Ltd. All rights reserved.